The Role of the Advanced Patient Derived Models in Tumors and Translational Medicine
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: closed (20 December 2023) | Viewed by 1777
Special Issue Editor
Special Issue Information
Dear Colleagues，
To develop a reliable tool for personalized cancer therapy and innovative drug development, the key features of the original tumor must be preserved in vitro over time. Recapitulation of the tissue microenvironment (TME) is challenging in vitro but necessary for the development of experimental cancer models. The translational gap between the preclinical and clinical domains could be improved with excellent outstanding in vitro cell models. Not only different cells from a patient, but also downsizing of tumor models using microfluidic platforms can be used to study the behavior and biology of cancer cells and optimally reflect the physiological environment in which they naturally occur. It is important to break new ground and move away from the old familiar cell lines that are far from the real in vivo situation The goal of this Special Issue is to present and promote advanced tumor models that can be reliably and reproducibly used in vitro and to make them available to the research community. Understanding these interactions can help to implement better therapeutic regimens for cancer treatment.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- Presenting highly characterized tumor cell lines which mimic the in vivo situation as close as possible;
- Establishing advanced tumor models, which can be used for the whole society;
- Determining the role of cancer-associated fibroblast in tumors by establishing adequate models;
- Using microfluidic platforms to minimize models.
We look forward to receiving your contributions.
Dr. Beate Rinner
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cell culture techniques
- cancer research
- tumor microenvironment and microfluidic
- tumor modeling
- patient derived models
